Chongqing Genrix Biopharmaceutical Co.,Ltd.(688443),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

688443 Chongqing Genrix Biopharmaceutical Co.,Ltd.

Closed 12-19 15:00:00

26.33

+0.13

+0.50%

High26.78	Low25.94	Vol2.17M
Open26.02	D1 Closing26.20	Amplitude3.21%
Mkt Cap9.66B	Tradable Cap3.08B	Total Shares367.00M
T/O57.19M	T/O Rate1.85%	Tradable Shares117.00M
P/B5.4	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688443","market":"SH","secType":"STK","nameCN":"Chongqing Genrix Biopharmaceutical Co.,Ltd.","latestPrice":26.33,"timestamp":1766127600000,"preClose":26.2,"halted":0,"volume":2166496,"delay":0,"changeRate":0.005,"floatShares":117000000,"shares":367000000,"eps":-1.5914,"marketStatus":"Closed","change":0.13,"latestTime":"12-19 15:00:00","open":26.02,"high":26.78,"low":25.94,"amount":57192000,"amplitude":0.0321,"askPrice":26.37,"askSize":40,"bidPrice":26.33,"bidSize":25,"shortable":0,"etf":0,"ttmEps":-1.5914,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":26.2,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":28.82,"lowLimit":23.58,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":366680000,"isCdr":false,"pbRate":5.4,"roa":"--","roe":"--","epsLYR":-2.17,"committee":0.123596,"marketValue":9655000000,"turnoverRate":0.0186,"status":0,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2025-12-22.","afterMarket":{"amount":0,"volume":0,"close":26.33,"buyVolume":0,"sellVolume":0,"time":1766129639585,"indexStatus":"Closed 12-19 15:30:00","preClose":26.2},"floatMarketCap":3072000000},"requestUrl":"/m/hq/s/688443/tweets","defaultTab":"tweets","newsList":[{"id":"2589733353","title":"Genrix Biopharma's Selikizumab Added to China's National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589733353","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589733353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 16:37","pubTimestamp":1765183039,"startTime":"0","endTime":"0","summary":"Chongqing Genrix Biopharmaceutical  said its self-developed selikizumab injection has been included in China's 2025 national reimbursement drug list.The drug treats metastatic moderate to severe plaque psoriasis and ankylosing spondylitis, according to a Monday filing with the Shanghai bourse.The inclusion will take effect on Jan. 1, 2026.Shares of the pharmaceutical company were down 1% Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688443","BK0239","NHLD"],"gpt_icon":0},{"id":"1199986475","title":"Chongqing Genrix Biopharmaceutical (688443.SH): Sailiqi Monoclonal Antibody Injection Included in 2025 National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1199986475","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199986475?lang=en_us&edition=fundamental","pubTime":"2025-12-07 16:22","pubTimestamp":1765095732,"startTime":"0","endTime":"0","summary":"Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SH) announced that its self-developed Sailiqi Monoclonal Antibody Injection (Jinlixi) has been successfully included in the National Reimbursement...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688443"],"gpt_icon":0},{"id":"1162452129","title":"RSV Outbreak Drives Surge in Prevention Demand as Companies Race to Capture Infant Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1162452129","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162452129?lang=en_us&edition=fundamental","pubTime":"2025-10-12 08:02","pubTimestamp":1760227353,"startTime":"0","endTime":"0","summary":"As respiratory diseases enter their peak season, discussions about \"Respiratory Syncytial Virus (RSV)\" continue to surge across major social media platforms. According to surveillance data released...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02257","159982","LU1064130708.USD","688276","BK0046","LU2580892789.USD","BK0196","BK1515","BK1574","BK0239","BK1161","LU1064131003.USD","BK0070","LU1328615791.USD","300142","LU2580892862.HKD","LU2148510915.USD","688443","06660","BK0077","BK0188","300122"],"gpt_icon":0},{"id":"2569892367","title":"Chongqing Genrix Biopharmaceutical  Says It Signs Two Commercial Cooperation Agreements, to Receive Down Payments, Milestone Payments of up to About 510 Mln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2569892367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569892367?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:29","pubTimestamp":1758540558,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nL3N3V90SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2569789715","title":"BRIEF-Chongqing Genrix Biopharmaceutical Signs Commercial Cooperation Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2569789715","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569789715?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:29","pubTimestamp":1758540558,"startTime":"0","endTime":"0","summary":"BRIEF-Chongqing Genrix Biopharmaceutical Signs Commercial Cooperation AgreementsSept 22  - Chongqing Genrix Biopharmaceutical Co Ltd 688443.SS:SAYS IT SIGNS TWO COMMERCIAL COOPERATION AGREEMENTS, TO RECEIVE DOWN PAYMENTS, MILESTONE PAYMENTS OF UP TO ABOUT 510 MILLION YUAN Source textFurther company coverage: 688443.SS  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nL3N3V90SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2568423698","title":"Genrix Biopharmaceutical Gets Nod to Trial Autoimmune Disease Drug: Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568423698","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568423698?lang=en_us&edition=fundamental","pubTime":"2025-09-18 13:22","pubTimestamp":1758172972,"startTime":"0","endTime":"0","summary":"Chongqing Genrix Biopharmaceutical  received approval from China's National Medical Products Administration to conduct clinical trials on GR2301 injection, according to a Shanghai bourse filing on Thursday.The drug is being developed as a treatment for autoimmune diseases, such as vitiligo caused by dysregulated IL-15 expression.The pharmaceutical company's shares jumped less than 3% during afternoon trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"1181553731","title":"Chongqing Genrix Biopharmaceutical (688443.SH) Receives Clinical Trial Approval for GR2301 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1181553731","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181553731?lang=en_us&edition=fundamental","pubTime":"2025-09-17 16:50","pubTimestamp":1758099039,"startTime":"0","endTime":"0","summary":"Chongqing Genrix Biopharmaceutical Co.,Ltd. (688443.SH) announced that it has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration, granting approval...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2566929738","title":"Genrix Biopharma Achieves Primary Endpoints in Phase 3 Trial for Dermatitis Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2566929738","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566929738?lang=en_us&edition=fundamental","pubTime":"2025-09-12 15:52","pubTimestamp":1757663556,"startTime":"0","endTime":"0","summary":"Chongqing Genrix Biopharmaceutical's  Teliqibaimab injection achieved its primary endpoint in a phase 3 clinical trial, according to a Friday filing with the Shanghai bourse.The drug is indicated for the treatment of moderate to severe atopic dermatitis in adults, according to the drug company's filing.Shares closed 1% higher during afternoon trading on Friday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"1173751867","title":"Chongqing Genrix Biopharmaceutical Co.,Ltd. (688443.SH): New Drug Application for Taleqibamab Injection Accepted for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1173751867","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173751867?lang=en_us&edition=fundamental","pubTime":"2025-09-11 17:08","pubTimestamp":1757581700,"startTime":"0","endTime":"0","summary":"Chongqing Genrix Biopharmaceutical Co.,Ltd. (688443.SH) announced that its Taleqibamab injection (GR1802 injection) for moderate to severe atopic dermatitis in adults has recently achieved its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2566523529","title":"Chongqing Genrix Biopharmaceutical Gets China Nod for Lupus Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2566523529","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566523529?lang=en_us&edition=fundamental","pubTime":"2025-09-11 15:36","pubTimestamp":1757576168,"startTime":"0","endTime":"0","summary":"China's medical products administrator approved Chongqing Genrix Biopharmaceutical's (SHA:688443) clinical trial for its GR1803 injection for systemic lupus erythematosus, according to a Thursday fili","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"1137849409","title":"Chongqing Genrix Biopharmaceutical (688443.SH): GR2303 Injection Receives Clinical Trial Approval Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=1137849409","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137849409?lang=en_us&edition=fundamental","pubTime":"2025-09-08 16:48","pubTimestamp":1757321299,"startTime":"0","endTime":"0","summary":"Chongqing Genrix Biopharmaceutical Co.,Ltd. (688443.SH) announced that the company has recently received a Clinical Trial Approval Notice issued by the National Medical Products Administration. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2560921103","title":"Genrix Biopharmaceutical Gets China Clinical Trial Nod for Rhinitis Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2560921103","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560921103?lang=en_us&edition=fundamental","pubTime":"2025-08-20 20:04","pubTimestamp":1755691463,"startTime":"0","endTime":"0","summary":"Chinese authorities approved Chongqing Genrix Biopharmaceutical's  clinical trial for its GR1802 injection for seasonal allergic rhinitis, according to a Wednesday filing with the Shanghai bourse.The trial is intended for allergic rhinitis in adolescents, the filing said.The drug is also indicated for atopic dermatitis in adults, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, and allergic rhinitis, among others, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2559931794","title":"Chongqing Genrix Biopharmaceutical to Launch Phase Three Trial for Allergic Rhinitis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2559931794","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559931794?lang=en_us&edition=fundamental","pubTime":"2025-08-14 13:51","pubTimestamp":1755150678,"startTime":"0","endTime":"0","summary":"Chongqing Genrix Biopharmaceutical  will launch a phase three clinical trial for GR1802 Injection in seasonal allergic rhinitis.The move follows an end-of-phase two meeting with China's drug administrator, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2555041028","title":"Chongqing Genrix Biopharmaceutical Gets China Clinical Trial Nod for Rabies Jab","url":"https://stock-news.laohu8.com/highlight/detail?id=2555041028","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555041028?lang=en_us&edition=fundamental","pubTime":"2025-07-30 20:33","pubTimestamp":1753878827,"startTime":"0","endTime":"0","summary":"Chinese authorities approved Chongqing Genrix Biopharmaceutical's  clinical trial for its selevimab injection, according to a Wednesday filing with the Shanghai bourse.The anti-rabies passive vaccine is indicated for children and adolescents aged 2 to 18 years after suspected exposure to the virus, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"1150015479","title":"Chongqing Genrix Biopharmaceutical (688443.SH) Secures Clinical Trial Approval for Sleridimab Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1150015479","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150015479?lang=en_us&edition=fundamental","pubTime":"2025-07-29 16:44","pubTimestamp":1753778662,"startTime":"0","endTime":"0","summary":"Chongqing Genrix Biopharmaceutical Co., Ltd. announced its investigational drug Sleridimab Injection has received clinical trial authorization from regulatory authorities. This monoclonal antibody...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","BK1583","BK1576","BK1141","688443","BK0239"],"gpt_icon":0},{"id":"2548526384","title":"Chongqing Genrix Biopharmaceutical Gets China Clinical Trial Nod for Myeloma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2548526384","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548526384?lang=en_us&edition=fundamental","pubTime":"2025-07-03 20:19","pubTimestamp":1751545194,"startTime":"0","endTime":"0","summary":"China's state drug administration approved Chongqing Genrix Biopharmaceutical's (SHA:688443) clinical trial for a combination of the GR1803 injection with anti-CD38 monoclonal antibody, according to a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688443","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2023-06-20","address":"重庆市巴南区麻柳大道699号2号楼A区","stockEarnings":[{"period":"1week","weight":-0.0383},{"period":"1month","weight":-0.058},{"period":"3month","weight":-0.2098},{"period":"6month","weight":-0.0495},{"period":"1year","weight":-0.0313},{"period":"ytd","weight":0.0494}],"companyName":"重庆智翔金泰生物制药股份有限公司","boardCode":"AI0027","perCapita":"9231股","boardName":"医药制造业","registeredCapital":"36668万元","compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.0143},{"period":"3month","weight":0.0184},{"period":"6month","weight":0.1579},{"period":"1year","weight":0.1544},{"period":"ytd","weight":0.1607}],"survey":"　　重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产与销售。公司的主要产品是抗体药物。","serverTime":1766271001640,"listedPrice":37.88,"stockholders":"12640人(较上一季度增加7.75%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Chongqing Genrix Biopharmaceutical Co.,Ltd.(688443),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Chongqing Genrix Biopharmaceutical Co.,Ltd.(688443) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Chongqing Genrix Biopharmaceutical Co.,Ltd.,688443,Chongqing Genrix Biopharmaceutical Co.,Ltd.股票,Chongqing Genrix Biopharmaceutical Co.,Ltd.股票老虎,Chongqing Genrix Biopharmaceutical Co.,Ltd.股票老虎国际,Chongqing Genrix Biopharmaceutical Co.,Ltd.行情,Chongqing Genrix Biopharmaceutical Co.,Ltd.股票行情,Chongqing Genrix Biopharmaceutical Co.,Ltd.股价,Chongqing Genrix Biopharmaceutical Co.,Ltd.股市,Chongqing Genrix Biopharmaceutical Co.,Ltd.股票价格,Chongqing Genrix Biopharmaceutical Co.,Ltd.股票交易,Chongqing Genrix Biopharmaceutical Co.,Ltd.股票购买,Chongqing Genrix Biopharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Chongqing Genrix Biopharmaceutical Co.,Ltd.(688443),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Chongqing Genrix Biopharmaceutical Co.,Ltd.(688443) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction